How to Build a Fertility App: Cost, Features, and When to Build Custom

A reproductive endocrinologist at a mid-size IVF clinic has a problem. Her patients call the nursing line daily to ask whether they took their FSH injection at the right time. The clinic's patient portal shows appointment dates and billing statements. It does not show medication schedules, lab trends, or follicle measurements from yesterday's ultrasound. The nurses spend two hours a day on calls that a well-designed app would eliminate.

Glow and Ovia are not the answer. They are consumer apps for people tracking cycles at home. They cannot pull E2 data from a clinic's EMR or send a push notification when an hCG trigger shot is due. The clinical workflow is a different product category entirely.

How much does it cost to build a fertility app?

A fertility MVP with cycle tracking, BBT charting, OPK logging, cervical mucus tracking, and a HIPAA-compliant data layer costs $65K-$100K and takes 14-18 weeks. A full platform adding IVF protocol tracking, telehealth, and wearable sync runs $180K-$320K in 30-44 weeks. Clinic builds with full EMR integration start at $350K.

These ranges assume a dedicated team of 2 engineers, one product designer, and one QA engineer. They assume HIPAA-compliant infrastructure from day one and a reproductive data privacy architecture that accounts for post-Dobbs state law requirements.

Who actually builds a custom fertility app?

Consumer fertility apps serve a broad population of people tracking cycles, planning pregnancies, and monitoring reproductive health at home. Four specific operator types reach conditions where a consumer app stops working.

Fertility clinics running IVF and IUI cycles need a patient-facing app that connects to their EMR. The data that matters during a stimulation cycle is not cycle day counts. It is today's E2 level, yesterday's follicle sizes, tonight's injection dose, and the trigger shot timing. None of that data exists in a consumer app. It lives in the clinic's Epic or eClinicalWorks system. A custom app pulls it out through an HL7 FHIR API and surfaces it to the patient in a readable format.

Reproductive endocrinology practices building patient engagement tools need a middle layer between the clinical EMR (where clinicians work) and the patient's phone. The goal is fewer phone calls to the nursing line, higher medication adherence, and better patient satisfaction scores. Consumer apps cannot close this loop because they have no connection to the clinic's data.

Employer benefits platforms building fertility support as a managed benefit operate a different model entirely. Companies like Progyny and Maven Clinic provide fertility benefits to employees at self-insured employers. They need a platform that manages coverage authorization, connects employees to in-network clinics, tracks cycle outcomes for population-level reporting, and integrates with the employer's HR and benefits administration systems. This is a B2B2C product with a claims layer, not a consumer tracker.

Digital health startups targeting the TTC (trying to conceive) market with clinical-grade features sit in a middle category. They want the consumer reach of Flo or Ovia but with data quality, algorithmic precision, or condition-specific features (PCOS tracking, endometriosis symptom logging) that consumer apps do not prioritize. They are often the customers most likely to need FDA guidance before launch.

Ovia, Glow, and Natural Cycles vs. custom: when each is the right call

Before scoping a custom build, understand exactly what the off-the-shelf products do well and where they stop.

Ovia Fertility (now part of Labcorp) is a well-designed consumer cycle tracker with ovulation prediction, symptom logging, and TTC guidance. It has a large user base and established distribution. If your product goal is a standalone consumer app for people tracking cycles at home with no clinical workflow attached, Ovia's feature set covers the category and your competition would be formidable without a clear differentiation strategy.

Glow combines cycle tracking with a fertility community and some telehealth features. Its strength is consumer distribution and the community product. If your users want peer support alongside tracking, Glow has network effects that a new build would take years to replicate.

Natural Cycles is FDA-cleared as a contraceptive app (Class II SaMD, cleared via 510(k) K173542 in 2018). It uses basal body temperature plus an algorithm to determine fertile and non-fertile days. Natural Cycles demonstrates the FDA pathway for a fertility app making clinical claims. If your product makes contraceptive efficacy or diagnostic claims, Natural Cycles is the regulatory benchmark you need to study.

Build custom when you hit any of these conditions:

The app needs to display or interact with data that lives in a clinic's EMR. Consumer apps have no FHIR integration layer and no mechanism to pull patient-specific clinical data from an external system.

The app manages IVF medication schedules. Stim protocols vary by patient, change based on monitoring results, and require nurse approval for dose adjustments. This is a clinical workflow that needs a connection to the clinical team, not a static calendar.

The app makes contraceptive, diagnostic, or predictive clinical claims. Consumer apps that avoid clinical claims operate outside FDA oversight. The moment your product claims to predict fertile windows with a specific accuracy rate for contraceptive use, or claims to detect PCOS from cycle data, you are in SaMD territory.

The data model requires multi-provider access. An IVF cycle involves a reproductive endocrinologist, a nursing team, an embryologist, and sometimes a genetic counselor. Consumer apps are single-user. The access control model, data sharing permissions, and audit log requirements are categorically different.

Fertility app features: V1, V2, V3

V1: Launch (14-18 weeks, $65K-$100K)

The ovulation prediction algorithm choice matters. A rule-based sympto-thermal method is faster to build and easier to audit. An ML-based approach can improve prediction accuracy with longitudinal data but requires a labelled training dataset and a validation study before you can make accuracy claims. If your product will make any performance claim about prediction accuracy, the algorithm and its validation process need to be documented before launch.

V2: Growth (adds 16-24 weeks, $80K-$160K)

Wearable BBT integration deserves specific attention. Consumer-grade wearables like Oura Ring, Whoop, and Apple Watch measure skin temperature, not core temperature. The BBT measurement that matters for ovulation detection is a sublingual or vaginal temperature taken at the same time each morning before getting out of bed. Dedicated BBT devices (Tempdrop, Natural Cycles thermometer) are purpose-built for this. Integration with these devices adds $20K-$30K to a V2 scope. Budget it as a V2 item unless your core product claim depends on wearable-based BBT accuracy from day one.

V3: Scale (adds 20+ weeks, $120K+)

Reproductive data privacy: the compliance layer most teams miss

HIPAA is the baseline. It applies to fertility apps operated by or on behalf of covered entities (clinics, physicians, hospitals) and their business associates. HIPAA requires a signed Business Associate Agreement with every vendor that touches PHI, end-to-end encryption for data in transit and at rest, audit logs for data access, and a breach notification process.

But fertility data carries a separate risk layer that most digital health teams discover too late. Fertility data, specifically cycle dates, OPK results, IVF attempt history, embryo transfer records, and pregnancy loss records, is among the most sensitive reproductive health data a person can generate.

The 2022 Dobbs v. Jackson Women's Health Organization decision changed the legal risk profile for storing reproductive data. As of 2023, multiple states have enacted laws restricting the collection, disclosure, or retention of reproductive health data. A 2023 Georgetown Law Center on Privacy and Technology analysis identified that period-tracking and fertility app data could be sought in legal proceedings in states with restrictive reproductive health laws. The data category that creates the most legal risk includes dates of conception attempts, pregnancy outcomes, and embryo transfer records.

The architecture response for a responsible fertility app includes four requirements. First, encrypted storage with no plaintext fertility event data at the application layer. Second, no ad-tech SDK access to fertility-specific data. Ad SDKs (Meta Pixel, Google Analytics without server-side configuration) can leak user event data to advertising networks. A fertility app that sends period date events to an ad network exposes user data to third parties in a way users do not expect and regulators are actively examining. The FTC took enforcement action against BetterHelp in 2023 for sharing mental health data with Facebook and Snapchat for advertising purposes. The same risk applies to fertility apps.

Third, user-controlled data deletion that works end-to-end. A user who wants to delete their fertility history should be able to do so completely, including deletion from backups on a defined schedule. This requires an active data deletion process, not just a soft-delete flag in the primary database.

Fourth, a documented process for law enforcement data requests. When a law enforcement agency issues a subpoena or warrant for user fertility data, your team needs a process: legal review, narrow compliance with the specific request, user notification where permitted, and documentation. Consumer fertility apps that were not built with this process in mind have been asked to produce user data in legal proceedings. The architecture decision about where you store data and what encryption you use determines how much data you can actually produce in response to a lawful request.

FDA SaMD requirements for fertility apps

The FDA's regulatory position on fertility apps follows a clear logic. Consumer wellness apps that log data, track cycles, and provide general health information operate outside FDA oversight. Apps that make a specific clinical claim about contraceptive efficacy, diagnostic accuracy, or treatment outcomes may qualify as Software as a Medical Device.

Consumer fertility tracking apps (cycle logging, ovulation estimation, TTC guidance with no specific accuracy claims) do not require FDA clearance. The FDA's Digital Health Center of Excellence has confirmed this classification for apps that function as general wellness products.

Natural Cycles set the benchmark for contraceptive fertility apps. FDA cleared Natural Cycles in August 2018 via 510(k) clearance K173542, making it the first FDA-cleared birth control app. The clearance required clinical study data demonstrating a Pearl Index (pregnancy rate per 100 women-years of use) that met the agency's standard for a Class II contraceptive device. The clinical evidence package required for that clearance took several years to assemble.

If your app makes any of these claims, you are likely building an SaMD: a specific contraceptive efficacy percentage, a diagnostic claim about PCOS, premature ovarian insufficiency, or diminished ovarian reserve, a prediction claim about IVF success rates tied to the app's algorithm, or a treatment recommendation that goes beyond general wellness guidance.

AI-based ovulation prediction that advertises algorithmic accuracy creates a potential SaMD issue. An app that says "our algorithm predicts your ovulation day within a 24-hour window with 94% accuracy" is making a performance claim that implies clinical validation. The FDA may view that claim as evidence that the app functions as a medical device. The safer path is to make the prediction visible while framing it as an estimate rather than a clinical diagnosis, and to avoid specific numerical accuracy claims that imply the algorithm has been clinically validated.

The De Novo pathway is the realistic option for first-to-market fertility SaMD. If no predicate device exists for your specific product category (e.g., an AI diagnostic for a specific fertility condition), a De Novo request rather than a 510(k) submission is likely required. FDA's Digital Health Center of Excellence publishes a Q-submission program that allows pre-submission meetings to get regulatory clarity before you build.

Build note: The SaMD boundary is not about what the app technically does. It is about what the app claims. Two apps with identical cycle-tracking code can land on different sides of the FDA line based solely on the language used in the app store listing, the in-app UI, and the marketing materials. Regulatory review of your copy is as important as the technical architecture.

How fertility apps make money

The femtech and fertility care market was valued at approximately $18.8 billion globally in 2023 and is projected to reach $60.7 billion by 2030, growing at a CAGR of 18.2% (Grand View Research, 2023). Fertility care represents one of the fastest-growing verticals within this market, driven by rising rates of delayed parenthood and increasing insurance coverage mandates for fertility treatments in the United States.

Four revenue models apply to different product types:

Consumer subscription is the model used by Flo, Natural Cycles, and Ovia Premium. Monthly pricing for premium features runs $10-$15 per month or $50-$80 per year. The ceiling is the willingness of an individual consumer to pay for better cycle insights. The floor is that free cycle tracking is available in dozens of apps, so premium features need to be meaningfully differentiated.

Employer fertility benefits follow the Progyny and Maven Clinic model. An employer purchases a fertility benefit for its workforce at a per-employee-per-month (PEPM) rate. Published PEPM rates for fertility benefits run $30-$80 depending on the scope of coverage and the size of the employee population. The upside is large contract values and predictable B2B revenue. The downside is a 3-9 month sales cycle for enterprise accounts and the requirement to build a clinical network alongside the technology platform.

Clinical SaaS for fertility clinics and reproductive endocrinology practices prices at $8-$25 per active patient per month. This model requires deep integration with the clinic's EMR and a clear workflow improvement that the clinic's admin team can measure. The value proposition is nurse time saved on inbound calls, patient medication adherence rates, and patient satisfaction scores.

Data and research partnerships represent a long-term revenue stream for platforms with large longitudinal datasets. De-identified fertility and cycle data has value for pharmaceutical research, epidemiological studies, and fertility treatment outcome research. This revenue stream requires explicit consent architecture from day one and careful attention to the reproductive data privacy requirements described above.

How RaftLabs builds fertility apps

"The fertility app category splits into two completely different products," says Ashit Vora, co-founder of RaftLabs. "Consumer cycle tracking is a well-understood product space with strong incumbents. Clinic-facing fertility apps and employer benefits platforms are clinical workflow tools that need to connect to EMR systems, manage protocol data, and meet a compliance standard that consumer apps were never designed for. Those two builds have almost nothing in common at the architecture level."

We have built HIPAA-compliant digital health products across patient engagement, telehealth, and clinical workflow categories. For fertility specifically, the projects that reach us are operators who have either outgrown consumer apps or are building a product category that consumer apps were never designed to serve. A reproductive endocrinology practice that wants to give IVF patients real-time protocol tracking through their existing EMR is a different problem than a startup building a consumer ovulation tracker. We scope them differently, staff them differently, and approach the regulatory questions differently from the first call.

If you are building a fertility platform for a clinic, an employer benefits program, or a digital health startup with a clinical-grade product thesis, book a 30-minute scoping call. We will map the build, identify the regulatory questions you need to answer before writing code, and give you a realistic cost and timeline based on your specific workflow.